US Edition
'Immediately Practice-Changing' Trial in Small Cell Lung Cancer
6 Articles
6 Articles
MedPage Today
Anti-Aging, Acupuncture and Health News'Immediately Practice-Changing' Trial in Small Cell Lung Cancer
(MedPage Today) -- CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment of small cell lung cancer (SCLC), a practice-changing phase III trial showed. In patients whose...
ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers
Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed every year and 200,000 deaths occurring.The post ASCO 2025: DeLLphi-304 helps Amgen to pave the way for BiTEs in solid cancers appeared first on Clinical Trials Arena.
PharmaMar announces positive results from the study with lurbinectedin in combination with atezolizumab as a first-line maintenance treatment for adults with advanced small cell lung cancer (SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The study has achieved both primary objectives, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atez…
The combination of Zepzelca and Tecentriq in maintenance treatment reduces the risk of disease progression by 46%
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
